Genetic Biomarkers of Metabolic Detoxification for Personalized Lifestyle Medicine
- PMID: 35215417
- PMCID: PMC8876337
- DOI: 10.3390/nu14040768
Genetic Biomarkers of Metabolic Detoxification for Personalized Lifestyle Medicine
Abstract
Metabolic detoxification (detox)-or biotransformation-is a physiological function that removes toxic substances from our body. Genetic variability and dietary factors may affect the function of detox enzymes, thus impacting the body's sensitivity to toxic substances of endogenous and exogenous origin. From a genetic perspective, most of the current knowledge relies on observational studies in humans or experimental models in vivo and in vitro, with very limited proof of causality and clinical value. This review provides health practitioners with a list of single nucleotide polymorphisms (SNPs) located within genes involved in Phase I and Phase II detoxification reactions, for which evidence of clinical utility does exist. We have selected these SNPs based on their association with interindividual variability of detox metabolism in response to certain nutrients in the context of human clinical trials. In order to facilitate clinical interpretation and usage of these SNPs, we provide, for each of them, a strength of evidence score based on recent guidelines for genotype-based dietary advice. We also present the association of these SNPs with functional biomarkers of detox metabolism in a pragmatic clinical trial, the LIFEHOUSE study.
Keywords: LIFEHOUSE study; biomarkers; biotransformation; detoxification; environmental health; functional medicine; nutrigenomics; personalized lifestyle medicine; pragmatic clinical trials; single nucleotide polymorphisms.
Conflict of interest statement
J.J.L. is a co-owner of Personalized Medicine, Inc., which is a consultant for Metagenics, Inc. and a consultant for Nature’s Sunshine Products, Inc. (Lehi, UT, USA). P.M.S. is a consultant for Metagenics, Inc. (Aliso Viejo, CA, USA). D.M. (Deanna Minich) is an independent contractor for Organic India and Symphony Health, a consultant for Metagenics, Inc., and sits on the Board of Directors for the American Nutrition Association. J.M.O. is a consultant for Metagenics, Inc. B.E. is the president, CEO, and a board-member of Metagenics, Inc.
Figures

References
-
- Grimaldi K.A., van Ommen B., Ordovas J.M., Parnell L.D., Mathers J.C., Bendik I., Brennan L., Celis-Morales C., Cirillo E., Daniel H., et al. Proposed guidelines to evaluate scientific validity and evidence for geno-type-based dietary advice. Genes Nutr. 2017;12:35. doi: 10.1186/s12263-017-0584-0. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources